Title: Efficacy and Safety of Garenoxacin versus Moxifloxacin in Acute Exacerbation of COPD: A Comparative Study
Authors: Dr D C Punera, Dr Ajay Sinha, Dr Renu Khanchandani, Dr Bhavana Srivastava, Dr Reena Bhardwaj, Dr Siddharth Ahuja
DOI: http://dx.doi.org/10.18535/jmscr/v4i8.74
Abstract
Aim: The aim of the present study was to compare the efficacy and safety of Garenoxacin with that of Moxifloxacin for the treatment of patients of Acute exacerbations of COPD.
Material and Method: This study was a prospective, open label, observational, comparative study; where clinically diagnosed COPD patients of either sex in age group of 25-70 years with clinical symptoms suggestive of Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) were enrolled. After obtaining written informed consent, Patients were divided into two treatment groups. Group A Moxifloxacin 400 mg once daily for 5 days while group B received Garenoxacin 400 mg once daily for 5 days. Primary outcome measure (cure, improved, failure), that is clinical success rate is assessed at day 14.
Result: Mean age (± 2SD) of the COPD patients in Garenoxacin group was 60.98 ± 10.67 whereas in Moxifloxacin group the mean age (± 2SD) was 57.80 ± 10.27. In Garenoxacin group, 14 patients achieved cure and rest 36 patients achieved improved whereas in Moxifloxacin group, 8 patients achieved cure, 41 patient achieved improvement and 1 patient did not respond to treatment and was termed failure. Observed adverse event were few, mild and self limiting in both group.
Conclusion: 5-day course of Garenoxacin is therapeutically comparable to Moxifloxacin in terms of clinical effectiveness in AECOPD.
Keywords- Acute exacerbations of COPD, Garenoxacin, Moxifloxacin.
References
1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370:741.
2. Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults--United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:938.
3. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006; 367:1216.
4. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-280.
5. Preston S. L., Drusano G. L., Berman A. L., Fowler C. L., Chow A. T., Dornseif B., Reichi V., Natarajan J., Corrado M. (1998) Pharmacodynamics of levofloxacin, a new paradigm for early clinical trials. JAMA 279:125–129.
6. Hajare A, Gupta A, Patil S, Krishnaprasad K, Bhargava A. A prescription event monitoring study on the utility of garenoxacin, a newer fluoroquinolone in India. International Journal of Applied and Basic Medical Research. 2015;5(2):87-91. doi:10.4103/2229-516X.157151.
7. Joan C. Fung-Tomc, Beatrice Minassian, Benjamin Kolek, Elizabeth Huczko, Lauren Aleksunes, Terry Stickle et al Antibacterial Spectrum of a Novel Des-Fluoro(6) Quinolone, BMS-284756. Antimicrob. Agents Chemother. December 2000 vol. 44 no. 12 3351-3356.
8. Hiroyasu Takagia, Kiyoshi Tanakab, Hisatsugu Tsudac, Hiroyuki Kobayashid. Clinical studies of garenoxacin. International Journal of Antimicrobial Agents Volume 32, Issue 6, December 2008, Pages 468–474.
9. Kraïm-Leleu M , Lesage FX , Drame M , Lebargy F , Deschamps F. Occupational Risk Factors for COPD: A CaseControl Study. PLoS One. 2016 Aug 3;11(8): e0158719. doi: 10.1371/journal.pone.0158719.)
10. Farah R, Khamisy-Farah R, Makhoul N. Survival of patients with worsening chronic obstructive pulmonary disease. Harefuah. 2016 Apr;155(4):205-9, 256.
11. John J. Reilly Jr.; Edwin K. Silverman; Steven D. Shapiro. Chronic Obstructive Pulmonary Disease. Chapter 260. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 18e. New York, NY: McGraw-Hill; 2012.
12. Anzueto A, Miravitlles M. Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respir Med. 2010 Oct;104(10):1396-403. doi: 10.1016/j.rmed.2010.05.018.)
13. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev. 2005;14:32–8
14. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF, Canadian Thoracic Society, Canadian Infectious Disease Society Can Respir J. 2003 Jul-Aug; 10 Suppl B():3B-32B.
15. Patel A, Wilson R. Newer fluoroquinolones in the treatment of acute exacerbations of COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2006;1(3):243-250.